{"ok":true,"data":{"subject":{"kind":"trial","nctId":"NCT04333407","title":"Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.","sponsor":"Imperial College London","phases":["NA"],"status":"TERMINATED","indication":null,"disease":"COVID-19"},"rows":[{"n":1,"question":"Is the biology right?","flags":[{"id":"somatic_driver","label":"Somatic driver evidence","value":"no","detail":"None of PTGS2, PTGS1, P2RY12, F10, HMGCR has somatic-mutation evidence in COVID-19","rule":"Open Targets has somatic-mutation evidence for the target in this cancer","source":{"label":"Open Targets: PTGS2 in COVID-19","url":"https://platform.opentargets.org/evidence/ENSG00000073756/MONDO_0100096","date":"2026-11-12T04:33:35.528Z"},"context":[]},{"id":"human_genetic","label":"Human genetic evidence","value":"no","detail":"No germline or somatic evidence for PTGS2, PTGS1, P2RY12, F10, HMGCR in COVID-19","rule":"Any germline or somatic human genetic evidence for the target in this cancer, counted apart from animal-model and literature evidence","source":{"label":"Open Targets: PTGS2 in COVID-19","url":"https://platform.opentargets.org/evidence/ENSG00000073756/MONDO_0100096","date":"2026-11-12T04:33:35.528Z"},"context":[]},{"id":"pediatric_target","label":"Pediatric target","value":"no","detail":"Not on the FDA list","rule":"Target is on FDA's Pediatric Molecular Target List (relevant targets); membership alone neither requires nor waives a study","source":{"label":"FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01))","url":"https://www.fda.gov/media/191157/download?attachment","date":"2026-11-11T07:05:03Z"},"context":[]},{"id":"haematologic","label":"Haematologic cancer","value":"no","detail":"Solid tumour","rule":"From the indication, or the registry conditions when no indication matches","source":{"label":"ClinicalTrials.gov NCT04333407","url":"https://clinicaltrials.gov/study/NCT04333407","date":"2026-11-12T04:33:35.528Z"},"context":[{"figure":"Likelihood of approval from phase 1: 7.5% haematologic vs 4.6% solid","dataset":"BIO / Informa / QLS 2021","years":"2011–2020","caveat":"Population-level, not a prediction."}]}],"facts":[{"label":"PTGS2 (via Aspirin)","text":"Evidence types in COVID-19: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc.","source":{"label":"Open Targets: PTGS2 in COVID-19","url":"https://platform.opentargets.org/evidence/ENSG00000073756/MONDO_0100096","date":"2026-11-12T04:33:35.528Z"}},{"label":"PTGS1 (via Aspirin)","text":"Evidence types in COVID-19: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc.","source":{"label":"Open Targets: PTGS1 in COVID-19","url":"https://platform.opentargets.org/evidence/ENSG00000095303/MONDO_0100096","date":"2026-11-12T04:33:35.528Z"}},{"label":"P2RY12 (via Clopidogrel)","text":"Evidence types in COVID-19: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc.","source":{"label":"Open Targets: P2RY12 in COVID-19","url":"https://platform.opentargets.org/evidence/ENSG00000169313/MONDO_0100096","date":"2026-11-12T04:33:35.528Z"}},{"label":"F10 (via Rivaroxaban)","text":"Evidence types in COVID-19: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc.","source":{"label":"Open Targets: F10 in COVID-19","url":"https://platform.opentargets.org/evidence/ENSG00000126218/MONDO_0100096","date":"2026-11-12T04:33:35.528Z"}},{"label":"HMGCR (via Atorvastatin)","text":"Evidence types in COVID-19: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc.","source":{"label":"Open Targets: HMGCR in COVID-19","url":"https://platform.opentargets.org/evidence/ENSG00000113161/MONDO_0100096","date":"2026-11-12T04:33:35.528Z"}}],"pending":[{"what":"Normal-tissue expression in vital organs","source":"Human Protein Atlas (ticket 36)"},{"what":"Pan-essential in cell lines","source":"DepMap (ticket 36)"},{"what":"Approved drug on this target","source":"Drugs@FDA (ticket 30)"}]},{"n":2,"question":"Can the result be trusted?","flags":[{"id":"randomised","label":"Randomised","value":"yes","detail":"Randomised allocation","rule":"Registry allocation field","source":{"label":"ClinicalTrials.gov NCT04333407","url":"https://clinicaltrials.gov/study/NCT04333407","date":"2026-11-12T04:33:35.528Z"},"context":[]},{"id":"small_denominator","label":"Small denominator","value":"no","detail":"320 enrolled; each patient moves a rate by 100 ÷ 320 = 0.3 points","rule":"Enrolment under 30; the arithmetic is shown, not a benchmark","source":{"label":"ClinicalTrials.gov NCT04333407","url":"https://clinicaltrials.gov/study/NCT04333407","date":"2026-11-12T04:33:35.528Z"},"context":[]},{"id":"primary_os","label":"Primary endpoint is overall survival","value":"no","detail":"All-cause mortality","rule":"A registered primary outcome measure names overall survival","source":{"label":"ClinicalTrials.gov NCT04333407","url":"https://clinicaltrials.gov/study/NCT04333407","date":"2026-11-12T04:33:35.528Z"},"context":[{"figure":"Non-OS primary endpoint: odds ratio 2.79 for a positive phase 3","dataset":"Otsuka 2021, 400 phase 3 oncology trials","years":"to 2020","caveat":"Shown with the next figure: a surrogate is easier to hit, and often a weak guide to survival."},{"figure":"52% of surrogate-to-OS correlations are low","dataset":"Prasad 2015","years":"published to 2014","caveat":"Shown with the figure above."}]},{"id":"results_overdue","label":"Results overdue","value":"yes","detail":"Primary completion 2021-11-30, 59 months ago; no results posted","rule":"Primary completion (actual) more than 12 months ago and no results posted to the registry","source":{"label":"ClinicalTrials.gov NCT04333407","url":"https://clinicaltrials.gov/study/NCT04333407","date":"2026-11-12T04:33:35.528Z"},"context":[{"figure":"40.9% of applicable trials report results within a year","dataset":"Results-reporting studies summarised in spec §11","years":"all therapy areas","caveat":"All areas, not oncology only."}]}],"facts":[],"pending":[{"what":"Treated and evaluable counts, assessor, confirmed response, follow-up and data cutoff","source":"Readout extraction (ticket 32)"},{"what":"Primary endpoint changed between registry versions","source":"Registry versions in the store (ticket 32)"}]},{"n":3,"question":"What must it beat?","flags":[],"facts":[],"pending":[{"what":"Control-arm result and approved therapies for the same segment, with label links","source":"Drugs@FDA, FDA labels and readouts (tickets 30, 32)"}]},{"n":4,"question":"Too crowded, or too late?","flags":[],"facts":[{"label":"Stopped on this target","text":"7 terminated, withdrawn or suspended trials of drugs against PTGS2; 2 give no reason. Reasons are quoted as the registry gives them on the target page.","source":{"label":"PTGS2: what already stopped","url":"/target/ENSG00000073756#stopped","date":"2026-11-12T04:33:35.584Z"}}],"pending":[{"what":"Programs on the target by phase and months behind the leader","source":"Programs and Drugs@FDA (ticket 33)"}]},{"n":5,"question":"Can it be approved, and stay approved?","flags":[{"id":"single_country","label":"Single-country","value":"yes","detail":"The only site is in United Kingdom","rule":"All listed sites are in one country; the share of US sites is shown","source":{"label":"ClinicalTrials.gov NCT04333407","url":"https://clinicaltrials.gov/study/NCT04333407?tab=locations","date":"2026-11-12T04:33:35.528Z"},"context":[]},{"id":"eu_pip","label":"EU paediatric investigation plan","value":"yes","detail":"EMA/PE/0000257220 (bempedoic acid;ezetimibe;atorvastatin, Treatment of mixed dyslipidaemia): W: decision granting a waiver in all age groups for all conditions or indications, 10 Jul 2025; EMA/PE/0000257216 (bempedoic acid;ezetimibe;atorvastatin, Treatment of elevated cholesterol): W: decision granting a waiver in all age groups for all conditions or indications, 10 Jul 2025; EMA/PE/0000238858 (acetylsalicylic acid;rivaroxaban, Prevention of atherothrombotic events): W: decision granting a waiver in all age groups for all conditions or indications, 16 Apr 2025; EMEA-003466-PIP01-23 (amlodipine;atorvastatin;Candesartan, Prevention of cardiovascular events): W: decision granting a waiver in all age groups for all conditions or indications, 1 Dec 2023; +32 more","rule":"An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-paediatric_investigation_plans-output-json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"eu_orphan","label":"EU orphan designation","value":"yes","detail":"EU/3/22/2714 positive 11 Nov 2022: Treatment of familial cerebral cavernous malformations","rule":"An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status","source":{"label":"EMA EU/3/22/2714","url":"https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2714","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"eu_authorised","label":"Authorised in the EU","value":"yes","detail":"Rivaroxaban Viatris (previously Rivaroxaban Mylan): authorised since 12 Nov 2021; Svariya (previously Rivaroxaban Koanaa): authorised since 21 Nov 2025; Xarelto: authorised since 30 Sept 2008; DuoPlavin: authorised since 14 Mar 2010; +35 more","rule":"An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"fda_orphan","label":"FDA orphan designation","value":"not published","detail":"FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the link","rule":"Would be: an FDA orphan designation names the drug","source":{"label":"FDA orphan designations search","url":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/","date":""},"context":[]},{"id":"fda_ped_approval","label":"FDA pediatric oncology approval","value":"no","detail":"FDA's table lists no pediatric approval of Aspirin, Clopidogrel, Rivaroxaban, Atorvastatin","rule":"FDA's Pediatric Oncology Drug Approvals table names the drug","source":{"label":"FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03)","url":"https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology-drug-approvals","date":"2026-11-12T04:33:35.594Z"},"context":[]},{"id":"studies_under_18","label":"Registered studies open to children","value":"yes","detail":"218 interventional studies of Aspirin, Clopidogrel, Rivaroxaban, Atorvastatin include patients under 18; 41 are recruiting, not yet recruiting or active","rule":"The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age","source":{"label":"ClinicalTrials.gov search","url":"https://clinicaltrials.gov/search?intr=%22Aspirin%22+OR+%22Clopidogrel%22+OR+%22Rivaroxaban%22+OR+%22Atorvastatin%22&aggFilters=ages%3Achild%2CstudyType%3Aint","date":"2026-11-12T04:33:35.599Z"},"context":[]}],"facts":[{"label":"Caveat","text":"Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where the sites are is a fact about the record, not a judgement of its quality."},{"label":"Cited case","text":"In February 2022 FDA asked its Oncologic Drugs Advisory Committee whether sintilimab's application, resting on ORIENT-11, a phase 3 run only in China, needed further trials showing it applies to US patients and US practice. One case, not a rule.","source":{"label":"FDA, ODAC 10 Feb 2022, draft questions","url":"https://www.fda.gov/media/156017/download","date":"2022-02-10"}},{"label":"Rare pediatric disease voucher","text":"FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news.","source":{"label":"FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs","url":"https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-designation-and-priority-review-voucher-programs","date":"2026-11-11"}}],"pending":[{"what":"Precedent approvals for target, modality and endpoint; accelerated-approval status","source":"Drugs@FDA and FDA accelerated-approval tables (ticket 30)"}]},{"n":6,"question":"Can the sponsor finish?","flags":[],"facts":[{"label":"Sponsor","text":"Imperial College London (academic or other)","source":{"label":"ClinicalTrials.gov NCT04333407","url":"https://clinicaltrials.gov/study/NCT04333407","date":"2026-11-12T04:33:35.528Z"}},{"label":"principal investigator","text":"Prapa Kanagaratnam, FRCP, PhD, Imperial College Healthcare NHS Trust","source":{"label":"Person page","url":"/person/Prapa%20Kanagaratnam%2C%20FRCP%2C%20PhD","date":"2026-11-12T04:33:35.528Z"}}],"pending":[{"what":"Filed cash, quarterly spend and the runway arithmetic","source":"SEC XBRL company facts (ticket 37)"},{"what":"Sponsor's completed vs stopped oncology trials and results-reporting record","source":"Registry, by company (ticket 37)"}]}],"limits":"Public records cannot show: sales forecasts; a probability of success for this asset; full deal terms and net prices; FDA designations and action dates before approval (shown only as company-reported); clinical holds unless the company disclosed them; manufacturing; patents on unapproved drugs; whether preclinical findings have been replicated.","sources":[{"label":"ClinicalTrials.gov NCT04333407","url":"https://clinicaltrials.gov/study/NCT04333407","date":"2026-11-12T04:33:35.528Z"},{"label":"Open Targets Platform","url":"https://platform.opentargets.org","date":"2026-11-12T04:33:35.528Z"},{"label":"FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01))","url":"https://www.fda.gov/media/191157/download?attachment","date":"2026-11-11T07:05:03Z"}]},"source":"ClinicalTrials.gov + Open Targets","fetchedAt":"2026-11-12T04:33:35.525Z"}